Seems like this deal alone will bank roll the company for sometime imo. It's great that we have no forseable dilution for 18 to 24 months imo.
"AGC already has existing relationships with many major pharmaceutical businesses and this will facilitate our discussions with Japanese pharmaceutical and healthcare companies in securing licensing opportunities for the clinical development and
commercialisation of Progenza in Japan.
Regeneus Japan, in association with both partners will be responsible for licencing clinical partners."
RGS Price at posting:
17.0¢ Sentiment: Buy Disclosure: Held
